Novo Nordisk
Page 7 of 9
HealthA billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
LifestyleNovo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
HealthMinnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
By Steve Karnowski and The Associated PressFebruary 8, 2024
RetailNovo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
FinanceEuropean stocks are giving off a ’90s vibe, Morgan Stanley says, and it could set them on a path to 16% returns in 2024
By Ryan HoggFebruary 6, 2024
RetailNovo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By Prarthana PrakashFebruary 5, 2024
RetailNovo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
HealthNorth Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
HealthOzempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By Ellie Harmsworth and BloombergDecember 24, 2023
HealthNovo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival
By Christian Wienberg and BloombergDecember 13, 2023
FinanceRoche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By Paula Doenecke and BloombergDecember 4, 2023
HealthPfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
HealthWegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
Most Popular
